EcoDrugPlus

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSCDRG00005014935
Gene Symbol: ACHE
3 Cross references
234 Possible Orthologues:

Activin A Receptor Like Type 1

Ensembl ID : ENSCDRG00005012249
Gene Symbol: ACVRL1
1 Cross references
358 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSCDRG00005018161
Gene Symbol: ACVR2B
1 Cross references
259 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSCDRG00005022066
Gene Symbol: ADORA1
3 Cross references
275 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSCDRG00005022047
Gene Symbol: ADORA2A
3 Cross references
264 Possible Orthologues:

Adenosine A2b Receptor

Ensembl ID : ENSCDRG00005016486
Gene Symbol: ADORA2B
1 Cross references
201 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSCDRG00005013531
Gene Symbol: ADA
3 Cross references
219 Possible Orthologues:

Adrenoceptor Alpha 1a

Ensembl ID : ENSCDRG00005019146
Gene Symbol: ADRA1A
3 Cross references
201 Possible Orthologues:

Adrenoceptor Alpha 1b

Ensembl ID : ENSCDRG00005010528
Gene Symbol: ADRA1B
1 Cross references
265 Possible Orthologues:

Adrenoceptor Alpha 1d

Ensembl ID : ENSCDRG00005009278
Gene Symbol: ADRA1D
1 Cross references
196 Possible Orthologues:

Adrenoceptor Alpha 2a

Ensembl ID : ENSCDRG00005005766
Gene Symbol: ADRA2A
1 Cross references
227 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSCDRG00005019961
Gene Symbol: ADRA2B
1 Cross references
222 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).